TITLE

INEX'S CALIFORNIA HEARING RESCHEDULED TO JANUARY, 2007

PUB. DATE
January 2007
SOURCE
Worldwide Biotech;Jan2007, Vol. 19 Issue 1, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the ruling of the British Columbia Supreme Court on the spin-out of Tekmira Pharmaceuticals Corp. by INEX Pharmaceuticals Corp. The court approved the INEX Plan of Arrangement to transfer its assets and liabilities to Tekmira. The motions raised by Protiva to block the spin-out have been rejected by the court.
ACCESSION #
23549868

 

Related Articles

  • Tekmira and Protiva sign share purchase agreement.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p14 

    The article reports on the share purchase agreement signed between Tekmira Pharmaceuticals Corp. and Protiva Biotherapeutics Inc. The two companies will combine their businesses by Tekmira purchasing the outstanding equity of privately owned Protiva. Part of the agreement is the investment of $5...

  • Tekmira, Provita Merge to Form RNAi Powerhouse.  // Bioworld Week;4/7/2008, Vol. 16 Issue 14, p2 

    The article reports that Tekmira Pharmaceuticals Corp. and Protiva Biotherapeutics Inc. based in British Columbia have merged to develop global leader in RNA interference (RNAi) therapeutics. Under the agreement, both firms will combine their businesses by Tekmira purchasing the outstanding...

  • Inex completes Tekmira spin-out.  // PharmaWatch: Biotechnology;Jun2007, Vol. 6 Issue 6, p18 

    The article reports that Inex Pharmaceuticals Corp. has completed the separation of its biotechnology subdivision Tekmira Pharmaceuticals Corp. and new common shares of Tekmira have begun trading on the Toronto Stock Exchange in Ontario. According to the company, it will be seeking opportunities...

  • Enzon terminates Inex agreements.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p15 

    Reports that Enzon Pharmaceuticals (EP) has terminated its partnership with Inex Pharmaceuticals Corp. (IPC) for the development and commercialization of Inex's proprietary oncology product, Marqibo. Agreement of EP on contractual obligations, including development expenses and milestone...

  • FINANCINGS ROUNDUP.  // BioWorld Today;7/6/2007, Vol. 18 Issue 130, p5 

    This section offers news briefs on pharmaceutical industry financing. About 3.5 million shares of restricted common stock has been sold by Dragon Pharmaceutical Inc. to a vendor for about $1.5 million. A shelf offering has been filed by ISTA Pharmaceuticals Inc. to sell up to $100 million worth...

  • Tekmira AddS RNAi For Alcohol Dependence.  // Worldwide Biotech;Apr2012, Vol. 24 Issue 4, p3 

    This article reports on the launch of a new RNA interference (RNAi) therapeutic from Tekmira Pharmaceuticals Corp. that targets aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol dependence.

  • Clinic Roundup.  // BioWorld Today;8/13/2013, Vol. 24 Issue 154, p7 

    The article reports on the launch of a Phase I/II trial of the oncology drug of Canadian pharmaceutical firm Tekmira Pharmaceuticals Corp. for patients with adrenocortical carcinoma and advanced gastrointestinal neuroendocrine tumors (GI-NET).

  • Clinic Roundup.  // BioWorld Today;10/18/2013, Vol. 24 Issue 201, p9 

    The article reports that Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia has priced up an underwritten of approximately 3.7 million shares of common stock at 8 dollar each, for 30 million dollars in gross proceeds.

  • Tekmira Tumbles On Ominous Signs For Ebola Drug. AMY REEVES // Investors Business Daily;6/19/2015, p00 

    The article reports on the financial performance of biopharmaceutical company Tekmira Pharmaceuticals Corp. as of June 2015, highlighting its decreased sales following an update on its Ebola program which resulted a loss of investor confidence.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics